Spots Global Cancer Trial Database for Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors
Official Title: A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors
Study ID: NCT06242691
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
South Texas Accelerated Research Therapeutics (START) ( Site 0005), San Antonio, Texas, United States
The Alfred Hospital ( Site 0103), Melbourne, Victoria, Australia
Rambam Health Care Campus-Oncology Division ( Site 0602), Haifa, , Israel
Hadassah Medical Center ( Site 0604), Jerusalem, , Israel
Rabin Medical Center-Oncology ( Site 0603), Petah Tikva, , Israel
Sheba Medical Center ( Site 0605), Ramat Gan, , Israel
Sourasky Medical Center ( Site 0601), Tel Aviv, , Israel
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
